An Open-Label Study to Determine the Maximum Tolerated Dose of Oral ESK-440 Administered As a Single Agent in Patients with Advanced or Metastatic Solid Tumors
Neoplasia (New York, NY)（2025）
Key words
Anaplastic lymphoma kinase (ALK),Focal adhesion kinase (FAK),Solid tumors,ESK-440,Tyrosine kinase inhibitor (TKI)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined